Corbus reports 42.9% ORR for CRB-701 in second-line oropharyngeal cancer

Corbus Pharmaceuticals announced updated Phase 1/2 data showing CRB-701 demonstrated robust activity in second-line oropharyngeal and cervical cancers with confirmed response rates of 42.9% and 34.4% respectively, with a favorable safety profile. The company plans to initiate a registrational TEMPO-1 study in summer 2026, potentially advancing the ADC candidate toward commercialization in underserved HPV-driven tumor populations.